Survival Outcomes of Breast Cancer in Sudanese Women: A Hospital-Based Study

Muddather, Hiba F.; Elhassan, Moawia Mohammed Ali; Faggad, Areeg

doi:10.1200/go.20.00538

Cited by 13 publications

(22 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this study, the mean age of patients was 50 ± 11.7 years. This finding is in line with previous studies which reported that most BC patients were above 45 or 50 years old, and the disease frequently occurs in women around menopause [27][28][29][30][31]. However, BC can strike at any age; and 4% of cases occur in women under 40 years old [32].…”

Section: Discussionsupporting

confidence: 91%

Impact of anticancer therapy on the quality of life of Sudanese patients with breast cancer at Khartoum oncology hospital

Aldaak

Suliman

Abd-Elgadir³

et al. 2022

BMC Women's Health

View full text Add to dashboard Cite

Background Chemotherapy-related toxicity affects the quality of life (QOL) of patients with cancer. Measuring the QOL in breast cancer (BC) patients has been the focus of clinical practices and research in recent decades. This study aimed to assess the impact of BC medications on QOL of Sudanese patients with BC. Methods A cross-sectional study was conducted in Khartoum Oncology Hospital, Sudan, from November 2020 to March 2021. All patients diagnosed with BC were included in the study. QOL was assessed using the European Organization for Research and Treatment of Cancer quality of life (EORTC QLQ-C-30) and breast cancer supplementary module (QLQ-BR23). ANOVA, independent t-test and logistic regression analysis were used to assess the association between variables. Results Two hundred patients were enrolled in the study, with a mean age of 50 ± 11.7 years. 52.5% of the patients were on a conventional therapy whereas 40.5% and 7% received hormonal and HER2-targeted therapies, respectively. In QLQ-C30 scale, the global health-QOL status score was (53.2 ± 1.9), with 54.0% of patients having poor global health-QOL status. In the functional scale, the cognitive functioning was the highest score (80.7 ± 1.8). In QLQ-C30 symptom scale, the most distressing issue was financial difficulties (63.7 ± 2.9). In QLQ-BR23 scale, body image scored the worse functioning (47.7 ± 2.7), with 54.5% of patients having poor QOL. In QLQ-BR23 symptoms scale, “being upset by hair loss” was the highest disturbing symptom (62.1 ± 3.3), with 68.6% of patients having poor QOL. Global health status (P = 0.000), social (P = 0.000), emotional (P = 0.002) and role functioning (P = 0.000) were significantly higher in patients taking HER2-targeted or hormonal therapy compared to conventional therapy. The level of symptomatology was significantly low in patients taking HER2-targeted therapy or hormonal therapy (P = 0.000) than those on conventional therapy. Hormonal (OR = 3.7, p = 0.01) and HER2-targeted therapies (OR = 10.2, p = 0.04 ) were positive predictors of QOL. Conclusion BC survivors in Sudan had a low QOL/global health status. Hormonal and HER2-targeted therapies were predictors of good QOL.

show abstract

Section: Discussionsupporting

confidence: 91%

Impact of anticancer therapy on the quality of life of Sudanese patients with breast cancer at Khartoum oncology hospital

Aldaak

Suliman

Abd-Elgadir³

et al. 2022

BMC Women's Health

View full text Add to dashboard Cite

show abstract

“…In this study, the mean age of patients was 50 ± 11.7 years. This nding is in line with previous studies which reported that most breast cancer patients were above 45 or 50 years old, and breast cancer frequently occurs in women around menopause [29][30][31][32][33]. However, breast cancer can strike at any age; and 4% of breast cancer cases occur in women under 40 years old [34].…”

Section: Discussionsupporting

confidence: 91%

Impact of anticancer therapy on the quality of life of Sudanese patients with breast cancer at Khartoum oncology hospital

Aldaak

Suliman

Abdoon

2022

Preprint

View full text Add to dashboard Cite

Background: Cancer treatment-related side effects affect quality of life (QOL) of patients. QOL has increasingly become a primary outcome measure for treatment efficacy. This study aimed to assess the impact of various anticancer therapies on QOL of Sudanese patients with breast cancer. Methods: A cross-sectional study was conducted in Khartoum Oncology Hospital, Sudan, from November 2020 to March 2021. All patients diagnosed with breast cancer were included in the study. QOL was assessed using European Organization for Research and Treatment of Cancer quality of life (EORTC QLQ-C-30) and breast cancer supplementary module (QLQ-BR23). ANOVA, independent t-test and logistic regression analysis were used to assess the association between variables. Results: 200 patients were enrolled in the study, with a mean age of 50±11.7 years. 52.5% of the patients were on a conventional therapy whereas 40.5% and 7% received hormonal and HER2-targeted therapies, respectively. In QLQ-C30 scale, the global health status score was (53. 2±1.9), with 54.0% of patients having poor global health status. In the functional scale, the cognitive functioning was the highest score (80.7±1.8). In QLQ-C30 symptom scale, the most distressing issue was financial difficulties (63.7±2.9). In QLQ-BR23scale, body image (47.7±2.7) scored the worse functioning, with 58.5% of patients having poor QOL. In QLQ-BR23 symptoms scale, "being upset by hair loss" was the highest disturbing symptom (62.1±3.3), with 68.5% of patients having poor QOL. Global health status (P=0.000), social (P=0.000), emotional (P=0.002) and role functioning (P=0.000) were significantly higher in patients taking HER2-targeted or hormonal therapy compared with conventional therapy. The level of symptomatology was significantly low in patients taking HER2-targeted therapy or hormonal therapy (P=0.000) when compared with conventional therapy. Hormonal (OR=3.88, p=0.005) and HER2-targeted therapies (OR=10.8, p=0.032) were positive predictors of QOL.Conclusion: Breast cancer survivors in Sudan had a low QOL/global health status. Hormonal and HER2-targeted therapies were predictors of good QOL.

show abstract

“…In Sudan, the majority of cancer patients have locally advanced or metastatic disease at presentation [ 8 – 13 ]. Currently available data from Sudan suggest that 90% of the terminally ill cancer patients suffered from uncontrolled pain [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

Adverse events of opioids for cancer-related pain in a resource-limited setting: a cross-sectional study from Sudan

Elhassan¹,

Mohammed²,

Omer³

et al. 2022

ecancer

View full text Add to dashboard Cite

Aim Data on the adverse events of opioids for cancer-related pain in Sudanese patients are limited. We conducted this study to evaluate the pattern and severity of adverse events of immediate release morphine, and tramadol used in the treatment of cancer-related pain. A secondary aim was to determine the response rate to opioids for pain control in cancer patients treated at the National Cancer Institute-University of Gezira (NCI-UG), Sudan. Methods This descriptive cross-sectional study was conducted at NCI-UG between 12 March 2019 and 12 May 2019. A pre-designed questionnaire was used to collect the clinical data of cancer patients on oral opioids for pain control during the study periods. Chi square test was applied to determine whether there is a significant association between the adverse events and the demographic/clinical variables. p value < 0.05 was considered statistically significant in all analyses. Results One-hundred and thirteen patients were screened in the study. Of these, three suffered from cognitive dysfunction and ten patients declined to participate in the study. Thus, 100 patients met the criteria for inclusion in this study. Breast cancer was the most frequent diagnosis (17%) followed by colorectal cancer (16%). The majority (91%) of patients had advanced or metastatic disease. The most frequently reported opioids-related adverse events were dry mouth (68%), constipation (61%), sedation (49%), nausea (31%) and vomiting (24%). Most of these symptoms were graded as mild to moderate and no patient had grade IV or V adverse events. Constipation and dry mouth were more frequent among patients received morphine compared to patients received tramadol ( p value < 0.005). Pain was controlled in 36% of patients, improved in 53% and not controlled in 11% of them. Conclusion This study shows a high prevalence of opioids-related adverse events. The majority of the opioids-related adverse events were grade I or grade II. There seem to be differences in the prevalence of opioids-related adverse events between patients receiving tramadol and those treated with morphine. Moreover, suboptimal pain control adds to the burden on already limited health resources. Therefore, the adequacy of cancer pain management in our setting should be systematically evaluated and effective cancer pain management programmes should be developed.

show abstract

Survival Outcomes of Breast Cancer in Sudanese Women: A Hospital-Based Study

Cited by 13 publications

References 50 publications

Impact of anticancer therapy on the quality of life of Sudanese patients with breast cancer at Khartoum oncology hospital

Impact of anticancer therapy on the quality of life of Sudanese patients with breast cancer at Khartoum oncology hospital

Impact of anticancer therapy on the quality of life of Sudanese patients with breast cancer at Khartoum oncology hospital

Adverse events of opioids for cancer-related pain in a resource-limited setting: a cross-sectional study from Sudan

Contact Info

Product

Resources

About